Skip links
Skip to content
Useful Links
Contact
Our Company
About Antisense
Our Strategy
Ionis Partnership
Management
Board of Directors
Our Science
ATL1102 for DMD
ATL1102 for MS
ATL1103 for Acromegaly
Other Indications
Technology Overview
Product Pipeline
Our Investors
Annual Reports
Broker & Other Reports
ASX Announcements
Company Presentations & Media
Company Directory
Corporate Governance
Latest News
Our Company
About Antisense
Our Strategy
Ionis Partnership
Management
Board of Directors
Our Science
ATL1102 for DMD
ATL1102 for MS
ATL1103 for Acromegaly
Other Indications
Technology Overview
Product Pipeline
Our Investors
Annual Reports
Broker & Other Reports
ASX Announcements
Company Presentations & Media
Company Directory
Corporate Governance
Latest News
Menu
Menu
[stock-market-ticker]
Our Company
About Antisense
Our Strategy
Ionis Partnership
Management
Board of Directors
Our Science
ATL1102 for DMD
ATL1102 for MS
ATL1103 for Acromegaly
Other Indications
Technology Overview
Product Pipeline
Our Investors
Annual Reports
Broker & Other Reports
ASX Announcements
Company Presentations & Media
Company Directory
Corporate Governance
Latest News
Useful links
Australian Multiple Sclerosis Society
Open Website
Australian Stock Exchange
Open Website
Muscular Dystrophy Foundation Australia
Open Website
Parent Project Muscular Dystrophy
Open Website
World Duchenne Organisation
Open Website
Acromegaly
Open Website
Ionis Pharmaceuticals Inc.
Open Website
Australian Multiple Sclerosis Society
Open Website
Latest Antisense
News & Updates.
All news & updates
4 weeks ago
Results of Annual General Meeting
4 weeks ago
Annual General Meeting 2023 Presentation
2 months ago
Online Meeting Guide for Annual General Meeting 15 November 2023
2 months ago
Notice of Annual General Meeting/Proxy Form
2 months ago
Antisense to participate in upcoming Industry Conferences
2 months ago
Launch of Share Sale Facility for Unmarketable Parcels
2 months ago
New Data Published, and Patent Filed, for ATL1102 in ‘Long COVID’
2 months ago
New Preclinical Data in ATL1102 for Limb Girdle Muscular Dystrophy R2
4 months ago
Antisense Share Purchase Plan raises $3.26M
4 months ago
Commencement of Chief Executive Officer
Adding {{itemName}} to cart
Added {{itemName}} to cart
Loading...
×